d.d. 14 december 2003: Bron: Medscape

Een lage dosis - 25 mg. per dag - DHEA (dehydroepiandrosterone) , een natuurlijk steroïd vaak gebruikt en voorgeschreven door orthomoleculaire artsen als voedingssupplement ter vervanging van extra hormoontherapie bij post-menopausale vrouwen (50 tot 65 jaar), verhoogt aldus studie de hormoonwaarden dusdanig goed dat het volgens de onderzoekers eerder als effectief medicijn aangemerkt zou moeten worden dan als voedingssupplement. "These data support and confirm that DHEA must be considered a valid compound and drug for 'hormone therapy' in postmenopausal women and not just a 'dietary supplement,' " they add. Een interessante stelling omdat DHEA in veel landen, o.a. in Amerika onder vuur ligt van de FDA - Federal Drug Administration. In Nederland is DHEA gewoon als voedingssupplement te koop in reformzaak of apotheek. Vooral voor borstkankerpatiënten en eierstokkankerpatiënten , maar wellicht ook voor prostaatkankerpatiënten een erg belangrijke ontwikkeling lijkt ons. 

Voor een ander natuurlijk middel te gebruiken voor een betere hormoonbalans leest informatie over DIM, welke literatuurlijst hieronder daaraan was toegevoegd , maar die wij ook hier bij de informatie over DHEA onderaan plaatsen, omdat er veel studies ook gaan over effect van DHEA (dehydroepiandrosterone).

Lees onderstaand abstract toegestuurd door een mailgroeplid (als OPS-lid kunt u gratis lid worden, d.d. december 2003 ca. 80 leden), waarvoor dank, en ook via ons lidmaatschap bij Medscape aan ons onder de aandacht gebracht. Het rapport is te medisch voor mij om dit letterlijk te vertalen, maar uw arts zal ongetwijfeld dit abstract begrijpen. 

Low-Dose DHEA Increases Androgen, Estrogen Levels in Menopause

Mindy Hung 
Medscape Medical News 2003. © 2003 Medscape 

Dec. 12, 2003 — Low-dose dehydroepiandrosterone (DHEA) administration increases adrenal hormone plasma levels in early and late menopause, according to results of a prospective case study published in the December issue of Fertility and Sterility.

"Although DHEA supplementation is not yet considered a medical treatment, this steroid has been demonstrated to induce specific metabolic effects and to increase both androgen and estrogen plasma levels in postmenopausal women," write Alessandro D. Genazzani, MD, PhD, and colleagues from the University of Modena in Italy.

The Italian team selected 20 healthy, postmenopausal patients, age 50 to 65 years, who were not using hormone replacements, for the 12-month prospective study. All patients received an ultrasound examination and a mammogram before the start of the study to exclude organic disease.

Dr. Genazzani and colleagues divided patients by age into two groups: early (aged 50-55 years, n = 10, group A) who were two to three years postmenopausal; and late (aged 60-65 years, n = 10, group B) who were five or more years postmenopausal. Five of the women were mild smokers.

All patients took 25 mg/day DHEA supplementation for 12 months. Every three months throughout the trial period, the investigators evaluated patients and drew blood samples to determine plasma levels of LH, FSH, E2, DHEA, DHEAS, androstenedione (A), testosterone, dihydrotestosterone, progesterone, 17 alpha-hydroxyprogesterone (17-OHP), allopregnanolone, estrone (E1), sex-hormone binding globulin (SHBG), cortisol (F), beta-endorphin, growth hormone (GH), and insuline-like grown factor-1 (IGF-1). 

Investigators also conducted a transvaginal ultrasound examination in each patient before and after 6 and 12 months of treatment to evaluate endometrial thickness. In addition, the researchers administered a Kupperman questionnaire to evaluate subjective vasomotor and psychological symptoms before and after 3, 6, and 12 months of therapy.

Younger postmenopausal subjects (group A) demonstrated higher levels of DHEA, DHEAS, testosterone, and beta-endorphin levels than older subjects (P < .05). Significant changes in endocrine levels were observed with therapy. DHEA treatment eliminated endocrine differences observed between the two groups at baseline. 

Testosterone and dihydrotestosterone plasma levels, and plasma E1 and E2 levels increased significantly and progressively in both groups. Investigators found no changes in SHBG concentrations in either group despite significant changes in A and E plasma concentrations. Allopregnanolone and beta-endorphin concentrations significantly increased in both groups. 

Cortisol F plasma levels progressively decreased throughout the study. Both groups also experienced significantly reduced LH and FSH plasma levels. GH and IGF-1 levels significantly increased in both groups. Supplementation did not induce changes in endometrial thickness.

At baseline, group A had higher values for subjective vasomotor disturbances and psychological disturbances than group B, whereas the latter had a higher score for psychological variables. Scores significantly improved in both groups during therapy. 

"The present study demonstrates the efficacy of low-dose DHEA administration of endocrine and psychoneuroendocrine parameters in early and late menopause and confirms that a low-dose DHEA supplementation increases adrenal androgens plasma levels (mainly DHEA and DHEAS), which are significantly impaired during menopause," Dr. Genazzani and colleagues write.

"These data support and confirm that DHEA must be considered a valid compound and drug for [hormone therapy] in postmenopausal women and not just a 'dietary supplement,' " they add.

Fertil Steril. 2003;80:1495-1501

Reviewed by Gary D. Vogin, MD


Voor een ander natuurlijk middel te gebruiken voor een betere hormoonbalans leest informatie over DIM, welke literatuurlijst hieronder daaraan was toegevoegd , maar die wij ook hier bij de informatie over DHEA plaatsen. 

Literatuur
1. Adlercreutz H, Western diet and Western diseases: some hormonal and biochemical mechanisms and associations. Scand J Clin Lab Invest. 1990; 50 (Suppl 21): 3-23.
2. Michnovicz JJ, et al., Dietary and pharmacological control of estradiol metabolism in humans. Ann N Y Acad Sci. 1990; 595:291-9.
3. Michnovicz JJ, et al., Altered estrogen metabolism and excretion in humans following consumption of indole-3-carbinol. Nutr Cancer. 1991;16(1):59-66.
4.Michnovicz JJ, et al., Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans. J Natl Cancer Inst. 1997 May 21; 89(10):718-23.
5. Bradlow HL, et al., 2-hydroxyestrone: the 'good' estrogen. J Endocrinol. 1996 Sep; 150 Suppl:S259-65.
6. Komura S, et al., Catecholestrogen as a natural antioxidant. Ann N Y Acad Sci. 1996 Jun 15; 786:419-429.
7. Zhu BT, et al., Is 2-Methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Research 1998 June 1; 58:2269-2277
8. Service RF, New role for estrogen in cancer? Science 1998 March 13; 279:1631-1633.
9. Steinmetz KA, Vegetables, fruit, and cancer prevention: a review. J American Dietetic Assoc. 1996; 10: 1027-39.
10. Farnsworth WE, Roles of estrogen and SHBG in prostate physiology. The Prostate 1996; 28:17-23.
11. Zeligs MA, Diet and estrogen status: the cruciferous connection. J of Medicinal Food 1998 Nov 2; 1: 67-82.
12. Bradfield CA and Bjeldanes LF, High performance liquid chromatographic analysis of anticarcinogenic indoles in Brassica oleracea. J Agric. Food Chem. 1987; 35:46-49.
13. Boyd JN, et al, Modification by beet and cabbage diets of aflatoxin B1 induced rat plasma alpha-fetoprotein elevation, hepatic tumorigenesis, and mutagenicity of urine. Food Chen Toxicol. 1982; 20: 47.
14.Wattenberg LW and Loub WD, Inhibition of polycyclic aromatic hydrocarbon-induced neoplasia by naturally occurring indoles. Cancer Research 1978; 38:1410-1413.
15. McDanell R, et al., Differential induction of mixed-function oxidase (MFO) activity in rat liver and intestine by diets containing processed cabbage: correlation with cabbage levels of glucosinolates and glucosinolate hydrolysis products. 1987 Food. Chem. Toxicicol.; 25: 363-368.
16. Guo D, Protection by chorophyllin and indole-3-carbinol against 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced DNA adducts and colonic aberrant crypts in the F344 rat. Carcinogenesis 1995; 16: 2931-2937.
17. Chen I, et al., Aryl hydrocarbon receptor-mediated antiestrogenic and antitumorigenic activity of diindolylmethane. Carcinogenesis 1998; 19: 1631-1639.
18. Telang NT, et al., Inhibition of proliferation and modulation of estradiol metabolism: novel mechanisms for breast cancer prevention by the phytochemical indole-3-carbinol. Proceedings of the Society for Experimental Biology and Medicine 1997; 216: 246-252.
19. Gamet-Payrastre L, et al., Selective cytostatic and cytotoxic effects of glucosinolates hydrolysis products on human colon cancer cells in vitro. Anti-Cancer Drugs 1998; 9: 141-148.
20. Kabat GC, et al., Urinary estrogen metabolites and breast cancer: a case-control study.
Cancer Epidemiol Biomarkers Prev. 1997 Jul;6(7):505-9.
21. Meilahn EN, et al., Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. British J of Cancer. 1998; 78: 1250-1255.
22. Ho GH, et al. Urinary 2/16 alpha-hydroxyestrone ratio: correlation with serum insulin-like growth factor binding protein-3 and a potential biomarker of breast cancer risk. Ann Acad Med Singapore 1998; 27:294-299.
23. Schneider J., et al., Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci USA 1982; 79: 3047-3051.
24. Zumoff B, et al., Estradiol transformation in men with breast cancer. J Clin Endocriol. Metab. 1966; 26: 960-966
25. Bradlow HL, et al., 16a hydroxylation of estradiol: a possible risk marker for breast cancer. Annals NY Acad. Sci. 1986; 464: 138-151.
26. Fishman, J, et al., Increased estrogen -16-hydroxylase activity in women with breast and endometrial cancer. Journal of Steroid Biochem. and Mol. Biol. 1984; 20: 1077-1081.
27. Sepkovic DW, et al., Estrogen metabolite ratios and risk assessment of hormone related cancers: assay validation and prediction of cervical cancer risk. Annals of the N.Y. Acad. of Science 1995; 768: 312-316.
28. Lahita, RG, et al., Increased 16a-hydroxylation of estradiol is systemic lupus erythematosus. J. Clin. Endocrinol. Metab. 1981; 53: 174-178. 
29. Ramsey-Goldman R, et al., Increased risk of malignancy in patients with systemic lupus erythematosus. J. of Investigative Medicine 1998; 46:217-222.
30. Hershcopf RJ, et al., Obesity, diet, endogenous estrogens, and the risk of hormone-sensitive cancer. Amer. J. of Clinical Nutrition. 1987; 45 (Supplement 1): 283-289.
31. Verhoeven, DTH, et al., Epidemiological studies on brassica vegetables and cancer risk. Cancer Epidemiology, Biomarkers & Prevention. 1996; 5: 733-748.
32. Kall, M.A., et al. Effects of dietary broccoli on human drug metabolizing enzymes : evaluation of caffeine, oestrone and chlorzoxazone metabolism. Carcinogenesis 1996; 17: 793-799.
33. Bradlow HL, et al., Long-term responses of women to inole-3-carbinol or a high fiber diet. Cancer, Epidemiology, Biomarklers & Prevention 1994; 3:591-595. 
34. Jellinck, PH, et al., Ah receptor binding properties of indole carbinols and induction of hepatic estradiol hydroxylation. Biochemical Pharmacology 1993; 45: 1129-1136.
35. Zeligs MA, Jacobs I, Facilitated absorption of a hydrophobic dietary supplement. Controlled Release Society Proceedings 1999: in press.
36. Wong YC, et al., Dose-ranging study of indole-3-carbinol for breast cancer prevention. J. of Cellular Biochemistry Supplenments. 1997; 28/29: 111-116. 
37. Spicer LJ and Hammond JM, Comparative effects of androgens and catecholestrogens on progesterone production by porcine granulosa cells. Molecular and Cellular Endocrinology 1988; 56: 211-217.
38. Tekpetey FR,and Armstrong DT, Catecholestrogen modulation of steroid production by rat luteal cells: mechanism of action. Molecular and Cellular Endocrinology 1994; 101: 211-217.
39. Niwa T, et al., Alterations in estradiol metabolism in MCF-7 cells induced by treatment with indole-3-carbinol and related compounds.Steroids 1994 Sep; 59(9):523-7.
40. Klauber N, et al. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Research 1997; 57:81-86.
41. Ge X, Yannai, S, Rennert, G, Gruener, N, and Fares, FA, 3,3'-Diindolylmethane induces apoptosis in human cancer cells. Biochemical and Biophysical Research Communications 1996; 228: 153-165.
42. Kerr JFR, et al., Apoptosis: its significance in cancer and cancer therapy. Cancer 1994; 73:3013-2026
43. Ettinger B, Overview of estrogen replacement therapy: a historical perspective. Proc. Soc. Exp. Biol. Med. 1998; 217:2-5.
44.Coldtiz GA, et al., The use of estrogens and progestins and the risk of breast cancer in postmenoapausal women. N.E.J.M. 1995; 332: 1589-93.
45. Colditz GA, Relationship between estrogen levels, use of hormone replacement therapy and breast cancer. J. Natl. Cancer Inst. 1998; 90: 814-23.
46. Labrie F., DHEA as physiological replacement therapy at menopause. J. Endocrinol. Invest. 1998; 21:399-401.
47.Labrie F, et al., Effect of 12-month dehydroepiandrosterone replacement therapy on bone, bagina, and endometrium in postmenopausal women. J. Clinical Endoc. Metab. 1997; 82:3498-3505.
48. Couillard S., et al., Inhibitory effect of dehydroepiandrosterone and of the novel antiestrogenEM-800 on the growth of hum ZR-75-1 breast cancer xenografts in nude mice. J. Natl. Cancer Inst. 1998;90:772-8. 
49. Zumoff B, Does postmenopausal estrogen administration increase the risk of breast cancer? Contributions of animal, biochemical, and clinical investigative studies to a resolution of the controversey. Proc. Soc. Exp. Biol. Med. 1998; 217: 30-37.
50. Ginsburg EL, et al., Effects of alcohol ingestion on estrogens in postmenopausal women. JAMA 1996; 276:1747-51. 
51. Calaf I, Alsina J, Benefits of hormone replacement therapy - overview and update. International J. of Fertility and Women's Medicine 1997; 42 Suppl 2: 329-46.
52. Grodstein F, et al., Postmenopausal hormone therapy and mortality. NEJM 1997; 336:1769-75
53. Inestrosa NC, et al., Cellular and molecular basis of estrogen's neuroprotection: potential relevance for Alzheimer's Disease. Molecular Neurobiology 1998; 17: 73-86.
54. Maxim P, et al., Fracture protection provided by long term estrogen replacement therapy. Osteoporosis Int. 1995; 5:23-29.
55. Manson JE, Postmenopausal hormone replacement and atherosclerotic disease. American Heart Journal 1994; 128:1337-43.
56. Spector TD, et al., Is hormone replacement therapy protective for hand and knee osteoarthritis in women? The Chingford study. Annals of the Rheumatic Diseases 1997; 56: 432-434.
57. Grodstein F, et al., Postmenopausal hormone use and risk for colorectal cancer and adenoma. Annals of Internal Medicine 1998; 128:705-12.
58.Krieg M., et al., Effect of aging on endogenous levels of 5-alpha-dihydrotestosterone, testosterone, estradiol and estrone in epithelium and stroma of normal and hyperplastic human prostate. J. Clin. Endocrinol. Metab 1993; 77: 375-381
59. Nakhla AM, et al., Estradiol activates the prostate androgen receptor and prostate-specific antigen secretion through the intermediacy of sex hormone binding globulin. J. of Biological Chemistry 1997; 272: 6838-6841
60. Brind J, Obese men have elevated plasma levels of estrone sulfate. Int. J. of Obesity 1990; 14: 483-486.
61. Klaiber EL, et al., Serum estrogen levels in men with acute myocardial infarction. American Journal of Medicine 1982; 73: 872-881.
62. Philips GB, Evidence for hyperoestrogenaemia as a risk factor for myocardial infarction in men. Lancet 1976; 2(7975): 14-18.
63. Phillips GB, et al., Association of hyperestrogenemia and coronary heart disease in men in the Framingham cohort. American J. of Medicine 1983; 74: 863-869.
64. Andersen P, et al., Reduced fibrinolytic capacity associated with low ratio of serum testosterone to oestradiol in healthy coronary high risk men. Scand. J. Haematol. 1983; 30 (Suppl 39): 53-57.
65. Reiser F., et al., Inhibition of normal and experimental angiotumor endothelial cell proliferation and cell cycle progression by 2-methoxyestradiol. Proc. Soc. Exp. Biol. Med. 1998; 219(3): 211-16.
66. Seeger H., et al., The effect of estradiol metabolites on the susceptibility of low density lipoprotein to oxidation. Life Sciences 1997; 61:865-868
67. Rose DP, et al., Effect of a low fat diet on hormone levels in women with cystic breast disease. II Serum radioimmunoassayable prolactin and growth hormone and bioactive lactogenic hormones. J. Natl. Cancer Inst. 1987; 78:627-631.
68. Hoyer AP, et al., Organochlorine exposure and risk of breast cancer. Lancet 1998 Dec 5; 352:1816-1820.
69. Bradlow HL, et al., Effects of pesticides on the ratio of 16 alpha/2-hydroxyestrone: a biologic marker of breasst cancer risk.Environ Health Perspect. 1995 Oct;103
Suppl 7:147-50.
70. Bradlow HL, et al. Role of the estrogen receptor in the action of organochlorine pesticides on estrogen metabolism in human breast cancer cell lines. Sci Total Environ. 1997 Dec 3; 208(1-2): 9-14.
71. Osborne MP, et al., Omega-3-fatty acids: modulation of estrogen metabolism and potential for breast cancer prevention. Cancer Investigation 1988; 8:629-631.
72. Bradlow HL, Michnovicz JJ, Telang NT, and Osborne MP, Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis 12, 1571-1574
73. Kojima T., et al., Chemoprevention of spontaneous endometrial cancer in female donryu rats by dietary indole-3-carbinol. Cancer Research 1994; 54: 1446-1449.
74. Chen I., et al., Indole-3-carbinol and diindolylmethane as aryl hydrocarbon (AH) receptor agonists and antagonists in T47D human breast cancer cells. Biochemical Pharmacology 1996; 51:1069-1076.
75. Davis DL, Bradlow HL, Can environmental estrogens cause breast cancer? Sci Am. 1995 Oct. 273(4): 167-72. Review.

Productinformatie:
90 vegetarische capsules à 100 mg. DIM met gepatenteerd afgiftesysteem met Vit. E en phosphatidylcholine.

Dosering (capsules tegelijk in te nemen tijdens een maaltijd):
Vrouwen i.v.m. hormoonbalans: * tot ca. 70 kilo 2 caps. 
* vanaf 70 kilo 3 caps.
Mannen i.v.m. hormoonbalans * tot ca. 70 kilo 3 caps.
* vanaf 70 kilo 4 caps.
Vrouwen i.v.m. gewichtsverlies * tot ca. 70 kilo 3 caps. 
* vanaf 70 kilo 4 caps.
Mannen i.v.m. gewichtsverlies * tot ca. 70 kilo 4 caps.
* vanaf 70 kilo 5 caps.

Voor meer informatie:
Springfield, Postbus 1574, 3260 BB Oud-Beijerland
tel. nr. 0186-626173, fax nr. 0186-621612,

estrogen, dhea, hormone, postmenopausal, estradiol, plasma, carbinol, indole, metabolism, indole-


Plaats een reactie ...

Reageer op "DHEA een uitstekend natuurlijk alternatief voor hormoontherapie bij postmenopausale vrouwen - 50 tot 65 jaar"


Gerelateerde artikelen
 

Gerelateerde artikelen

Alternatieve therapieën bij >> Algemeen: een intensief fitness >> Acupunctuur als aanvulling >> Voorlichtingsfilmpjes over >> Agaricus Blazei Murill een >> Aids - HIV en effect van voeding >> Aldara zalf - Imiquimod, een >> Aloe Vera naast chemo bij >> AMAS test - Anti Maligne Antibody >> Antioxidanten, voeding en >>